Uploaded March 2026 | Updated September 2026, 1 week ago

---

In the phase 3 ATOMIC trial in resected stage III mismatch repair–deficient colon cancer, adding atezolizumab to modified FOLFOX6 improved 3-year disease-free survival, with a higher incidence of grade 3 or 4 toxic effects, mainly fatigue.  

Read the full ATOMIC trial results and Research Summary at NEJM.org.

#oncology #gastroenterology #nejm